| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
|
| [2] |
Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023， 73(1)：17-48. DOI: 10.3322/caac.21763.
|
| [3] |
|
| [4] |
|
| [5] |
Stelloo E, Nout RA, Osse EM, et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the portec cohorts [J]. Clin Cancer Res, 2016, 22(16): 4215-4224. DOI: 10.1158/1078-0432.CCR-15-2878.
|
| [6] |
Kommoss S, McConechy MK, Kommoss F, et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series [J]. Ann Oncol, 2018, 29(5): 1180-1188. DOI: 10.1093/annonc/mdy058.
|
| [7] |
Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma [J]. Int J Gynecol Cancer, 2021, 31(1): 12-39. DOI: 10.1136/ijgc-2020-002230.
|
| [8] |
Raffone A, Travaglino A, Saccone G, et al. PTEN expression in endometrial hyperplasia and risk of cancer: a systematic review and Meta-analysis [J]. Arch Gynecol Obstet, 2019, 299(6): 1511-1524. DOI: 10.1007/s00404-019-05123-x.
|
| [9] |
|
| [10] |
Nakamura M, Obata T, Daikoku T, et al. The association and significance of p53 in gynecologic cancers: the potential of targeted therapy [J]. Int J Mol Sci, 2019, 20(21): 5482. DOI: 10.3390/ijms20215482.
|
| [11] |
Köbel M, Ronnett BM, Singh N, et al. Interpretation of P53 immunohistochemistry in endometrial carcinomas: toward increased reproducibility [J]. Int J Gynecol Pathol, 2019, 38 Suppl 1(Iss 1 Suppl 1): S123-S131. DOI: 10.1097/PGP.0000000000000488.
|
| [12] |
Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma[J]. Nature， 2013 ， 497(7447)：67-73. DOI: 10.1038/nature12113.
|
| [13] |
Lu J, Liang J, Xu M, Wu Z, et al. Identification of an eleven-miRNA signature to predict the prognosis of endometrial cancer [J]. Bioengineered, 2021, 12(1): 4201-4216. DOI: 10.1080/21655979.2021.1952051.
|
| [14] |
Donkers H, Hirschfeld M, Wei D, et al. Usefulness of microRNA detection in the diagnostics of endometrial cancer [J]. Acta Obstet Gynecol Scand, 2021, 100(6): 1148-1154. DOI: 10.1111/aogs.14141.
|
| [15] |
Lu Y, Tang W, Wang X, et al. Development of potential prognostic biomarkers based on DNA methylation-driven genes for patients with endometrial cancer [J]. Int J Gen Med, 2021, 14: 10541-10555. DOI: 10.2147/IJGM.S341771.
|
| [16] |
Huo X, Sun H, Cao D, et al. Identification of prognosis markers for endometrial cancer by integrated analysis of DNA methylation and RNA-Seq data [J]. Sci Rep, 2019, 9(1): 9924. DOI: 10.1038/s41598-019-46195-8.
|
| [17] |
Grassi T, Harris FR, Smadbeck JB, et al. Personalized tumor-specific DNA junctions to detect circulating tumor in patients with endometrial cancer [J]. PLoS One, 2021, 16(6): e0252390. DOI: 10.1371/journal.pone.0252390.
|
| [18] |
Susini T, Baldi F, Howard CM, et al. Expression of the retinoblastoma-related gene Rb2/p130 correlates with clinical outcome in endometrial cancer [J]. J Clin Oncol, 1998, 16(3): 1085-1093. DOI: 10.1200/JCO.1998.16.3.1085.
|
| [19] |
Mori M, Mori T, Yamamoto A, et al. Proliferation of poorly differentiated endometrial cancer cells through autocrine activation of FGF receptor and HES1 expression [J]. Hum Cell, 2019, 32(3): 367-378. DOI: 10.1007/s13577-019-00249-1.
|
| [20] |
Li BL, Lu W, Qu JJ, et al. Loss of exosomal miR-148b from cancer-associated fibroblasts promotes endometrial cancer cell invasion and cancer metastasis [J]. J Cell Physiol, 2019, 234(3): 2943-2953. DOI: 10.1002/jcp.27111.
|
| [21] |
Sootome H, Fujita H, Ito K, et al. Futibatinib is a novel irreversible FGFR 1-4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors [J]. Cancer Res, 2020, 80(22): 4986-4997. DOI: 10.1158/0008-5472.CAN-19-2568.
|
| [22] |
Ocak B, Atalay FÖ， Sahin AB, et al. The impact of Ki-67 index, squamous differentiation, and several clinicopathologic parameters on the recurrence of low and intermediate-risk endometrial cancer [J]. Bosn J Basic Med Sci, 2021, 21(5): 549-554. DOI: 10.17305/bjbms.2020.5437.
|
| [23] |
He X, Lei S, Zhang Q, et al. Deregulation of cell adhesion molecules is associated with progression and poor outcomes in endometrial cancer: analysis of the cancer genome atlas data [J]. Oncol Lett, 2020, 19(3): 1906-1914. DOI: 10.3892/ol.2020.11295.
|
| [24] |
Toumpeki C, Liberis A, Tsirkas I, et al. The role of arid1a in endometrial cancer and the molecular pathways associated with pathogenesis and cancer progression [J]. In Vivo, 2019, 33(3): 659-667. DOI: 10.21873/invivo.11524.
|
| [25] |
Brunner A, Riss P, Heinze G, et al. pHH3 and survivin are co-expressed in high-risk endometrial cancer and are prognostic relevant [J]. Br J Cancer, 2012, 107(1): 84-90. DOI： 10.1038/bjc.2012.198.
|
| [26] |
Flindris S, Katsoulas N, Goussia A, et al. The expression of NRIP1 and LCOR in endometrioid endometrial cancer [J]. In Vivo, 2021, 35(5): 2631-2640. DOI: 10.21873/invivo.12545.
|
| [27] |
Degez M, Caillon H, Chauviré-Drouard A, et al. Endometrial cancer: a systematic review of HE4, REM and REM-B [J]. Clin Chim Acta, 2021, 515: 27-36. DOI: 10.1016/j.cca.2020.12.029.
|
| [28] |
Yoriki K, Mori T, Kokabu T, et al. Estrogen-related receptor alpha induces epithelial-mesenchymal transition through cancer-stromal interactions in endometrial cancer [J]. Sci Rep, 2019, 9(1): 6697. DOI: 10.1038/s41598-019-43261-z.
|
| [29] |
van Weelden WJ, van der Putten LJM, Inda MA, et al. Oestrogen receptor pathway activity is associated with outcome in endometrial cancer [J]. Br J Cancer, 2020, 123(5): 785-792. DOI: 10.1038/s41416-020-0925-4.
|
| [30] |
Wang C, Tran DA, Fu MZ, et al. Estrogen receptor, progesterone receptor, and HER2 receptor markers in endometrial cancer [J]. J Cancer, 2020, 11(7): 1693-1701. DOI: 10.7150/jca.41943.
|
| [31] |
|